SLSN vs SKIN vs RVLV

For growth investors, Solesence, Inc.

Common Stock (SLSN) is the stronger pick with 40. 4% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). Solesence, Inc. Common Stock (SLSN) offers the better valuation at 18. 0x trailing P/E, making it the more compelling value choice. Analysts rate Revolve Group, Inc. (RVLV) a "Buy" — based on 30 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Solesence, Inc.

Common Stock (SLSN) is the cheapest at 18. 0x versus Revolve Group, Inc. at 23. 5x.

Over the past 5 years, Solesence, Inc.

Common Stock (SLSN) delivered a total return of -18. 2%, compared to -92. 7% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: SLSN returned +152. 0% versus SKIN's -91. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Revolve Group, Inc.

(RVLV) is the lower-risk stock at 1. 81β versus Solesence, Inc. Common Stock's 2. 02β — meaning SLSN is approximately 11% more volatile than RVLV relative to the S&P 500. On balance sheet safety, Revolve Group, Inc. (RVLV) carries a lower debt/equity ratio of 6% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Solesence, Inc.

Common Stock (SLSN) is pulling ahead at 40. 4% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: Solesence, Inc. Common Stock grew EPS 179. 0% year-over-year, compared to 24. 6% for Revolve Group, Inc.. Over a 3-year CAGR, SLSN leads at 21. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Solesence, Inc.

Common Stock (SLSN) is the more profitable company, earning 8. 1% net margin versus -3. 2% for The Beauty Health Company — meaning it keeps 8. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SLSN leads at 9. 8% versus -6. 9% for SKIN. At the gross margin level — before operating expenses — SKIN leads at 65. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RVLV: 44.

1% to $29. 10.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Revolve Group, Inc.

(RVLV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RVLV: -40. 6%, SKIN: -91. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SLSN (Consumer Defensive) and SKIN (Consumer Defensive) and RVLV (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SLSN is a small-cap high-growth stock; SKIN is a small-cap quality compounder stock; RVLV is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.